Emerging Molecule Offers Hope for Treating MASH, Endometriosis, and Other Chronic Conditions
A new small molecule, Bobcat339, shows promise in selectively targeting harmful macrophages associated with chronic diseases like MASH, endometriosis, and cancer, offering hope for innovative treatments.
Recent research highlights the potential of a small molecule, known as Bobcat339, in targeting harmful immune cells called macrophages that contribute to chronic diseases such as metabolic dysfunction-associated steatohepatitis (MASH), endometriosis, and certain cancers like non-small cell lung cancer (NSCLC). Macrophages are crucial for immune defense, but in chronic disease microenvironments, they can shift into a pathogenic state, exacerbating inflammation and tissue damage.
Scientists at Yale University have identified specific markers unique to these disease-promoting macrophages. They found that in disease states, the gene TET3 becomes overexpressed in these cells, leading to further immune dysregulation. Bobcat339 is designed to degrade the TET3 protein, selectively targeting pathogenic macrophages that overexpress this gene without harming protective macrophages. This specificity offers a promising therapeutic avenue.
The researchers exposed healthy human and mouse macrophages to disease-like conditions, prompting them to adopt harmful features. In these models, TET3 overexpression was a key factor, and Bobcat339 effectively targeted these disease-associated macrophages, reducing tissue damage, tumor growth, and lesion severity across multiple disease models.
The promising safety profile observed in animal studies suggests that Bobcat339 could move forward into human clinical trials. This molecule’s ability to modulate disease microenvironments by eliminating only the harmful macrophages may provide a versatile treatment option for various chronic inflammatory conditions.
Yale’s team is actively working on refining Bobcat339 and its derivatives to enhance potency and safety, aiming to develop an effective treatment for patients with limited options today. The discovery underscores the potential of epigenetic targeting in immunomodulation for complex chronic diseases.
Source: [https://medicalxpress.com/news/2025-09-molecule-mash-endometriosis-chronic-diseases.html]
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Expected Announcement on Autism by President Trump Sparks Debate
President Trump is expected to make a significant announcement about autism, prompting discussions on environmental factors and recent research findings. Experts urge cautious interpretation to avoid misinformation.
LGBTQ+ Inclusive Policies Boost Mpox Vaccination Rates Across U.S. States
A study reveals that states with stronger LGBTQ+ protections in the US saw significantly higher mpox vaccination rates during the 2022–2023 outbreak, highlighting the importance of inclusive policies in public health.
Investigation Uncovers Data Inaccuracies in Key Studies of Heart Medication Ticagrelor
A recent investigation by The BMJ highlights serious data discrepancies in pivotal studies supporting the approval of the widely used heart medication ticagrelor, raising concerns over its safety and efficacy.
Could HPV Be a Hidden Cause of Skin Cancer?
Emerging evidence suggests that human papillomavirus (HPV) may contribute to certain skin cancers, especially in individuals with immune deficiencies, expanding our understanding of skin cancer causes beyond UV radiation.